A study of nemolizumab for babies with eczema
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a medicine called nemolizumab for babies aged 6 to 23 months with moderate to severe eczema. The goal is to see if it reduces itching and improves skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is between 6 and 23 months old at the start of the study.
- Your baby has moderate to severe eczema diagnosed by a doctor.
- Your baby has not had enough relief from standard eczema creams or needs stronger treatment.
- You agree to apply moisturizer daily and follow the study schedule.
- Your baby weighs at least 11 pounds (5 kg).
- Your baby has not used certain strong eczema treatments or vaccines in the weeks before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medicine (nemolizumab) for people with moderate-to-severe eczema that hasn't been helped enough by topical treatments. It aims to reduce itching and skin symptoms. The trial will compare the drug to a placebo in Chinese participants.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
This trial tests whether a special skin imaging technique (reflectance confocal microscopy) can see how nemolizumab changes the skin structure in people with moderate-to-severe eczema. It may help researchers understand how this treatment works.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
This trial tests a daily pill called Abrocitinib to see if it can help children ages 6 to 11 with moderate-to-severe eczema that hasn't gotten better with creams or ointments. Eczema (also called atopic dermatitis) causes itchy, red skin, and this medicine might calm the immune response to reduce itching and rashes.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.